T1	Intervention 0 47	Ganitumab with either exemestane or fulvestrant
T2	Intervention 420 517	adding ganitumab to endocrine treatment for patients with hormone-receptor-positive breast cancer
T3	Intervention 700 743	previously treated with endocrine treatment
#1	AnnotatorNotes T3	Please note: Instructions regarding marking pre-treatment is not clearly given to me.
T4	Intervention 828 1062	intravenous ganitumab 12 mg per kg bodyweight or placebo in combination with open-label intramuscular fulvestrant (500 mg on day 1, then 250 mg on days 15, 29, and every 28 days) or oral exemestane (25 mg once daily) on a 28-day cycle
T5	Intervention 1491 1500	ganitumab
T6	Intervention 1521 1528	placebo
T7	Intervention 1611 1632	ganitumab and placebo
T8	Intervention 1790 1799	ganitumab
T9	Intervention 1818 1825	placebo
T10	Intervention 2070 2079	ganitumab
T11	Intervention 2112 2119	placebo
T12	Intervention 2453 2601	Addition of ganitumab to endocrine treatment in women with previously treated hormone-receptor-positive locally advanced or metastatic breast cancer
